Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

The valuation ratios exhibit a cyclical trajectory characterized by a period of significant expansion from March 2022 through June 2024, followed by a sharp contraction phase and a subsequent partial recovery leading into early 2026.

Price to Earnings (P/E) and Price to Operating Profit (P/OP)

A strong positive correlation is observed between the P/E and P/OP ratios. The P/E ratio climbed steadily from 9.15 in March 2022 to a peak of 27.88 in June 2024. Similarly, the P/OP ratio rose from 7.98 to a high of 30.86 during the same window. Both metrics experienced a substantial decline throughout late 2024 and the first half of 2025, with the P/E reaching a trough of 13.29 and the P/OP dropping to 15.42 by June 2025. A moderate recovery followed, with the P/E ending at 16.27 and the P/OP at 19.83 by March 2026.

Price to Sales (P/S)

The P/S ratio followed a similar growth and contraction pattern, increasing from 4.40 in March 2022 to a peak of 8.93 in June 2024. A subsequent correction occurred, driving the ratio down to 4.17 by June 2025, which represents a return to valuation levels seen at the beginning of the observed period. The ratio concluded the period at 4.82 in March 2026.

Price to Book Value (P/BV)

The P/BV ratio remained relatively stable between 3.21 and 3.96 for the first two years, peaking at 4.27 in June 2024. A marked compression in this multiple was evident starting in September 2024, falling to a period low of 1.98 by June 2025. While the ratio recovered to 2.29 by March 2026, it remained significantly lower than the multiples recorded between 2022 and 2024.

The price-to-earnings (P/E) ratio exhibited significant volatility and a cyclical pattern between March 2022 and March 2026. The valuation moved through three distinct phases: a prolonged period of expansion, a sharp correction, and a subsequent partial recovery.

P/E Ratio Expansion (March 2022 – June 2024)

A consistent upward trend in the P/E ratio was observed during this interval, rising from a low of 9.15 to a peak of 27.88. This expansion was primarily driven by a steady increase in share price, which climbed from 660.86 to 1,093.14. This growth in valuation occurred despite a simultaneous decline and subsequent stabilization of earnings per share (EPS), suggesting a market re-rating or increased investor optimism regardless of immediate earnings performance.

Valuation Correction and Contraction (June 2024 – June 2025)

Following the peak in mid-2024, a sharp contraction in the P/E ratio occurred, falling to 13.29 by June 2025. This decline was almost exclusively attributed to a substantial drop in the share price, which decreased from 1,093.14 to 558.87. During this same period, EPS remained relatively stable, fluctuating within a narrow range between 39.20 and 42.07, indicating that the valuation compression was driven by market sentiment rather than a deterioration in fundamental earnings.

Recovery and Stabilization (June 2025 – March 2026)

A moderate recovery in valuation was observed toward the end of 2025, with the P/E ratio increasing to 18.19 by December 31, 2025, as the share price rebounded to 775.06. The period concluded with a slight correction in March 2026, where the P/E ratio settled at 16.27, coinciding with a share price of 686.36 and a stable EPS of 42.19.

Earnings Per Share (EPS) Relationship

After an initial decline from 72.22 in March 2022 to 38.12 in March 2023, EPS exhibited a high degree of stability for the remainder of the analyzed period. The lack of significant variance in EPS from 2023 through 2026 confirms that the fluctuations in the P/E ratio were predominantly the result of share price volatility rather than shifts in the company's profitability.

The valuation of the equity relative to operating performance experienced significant volatility between March 2022 and March 2026. A distinct phase of valuation expansion was followed by a sharp correction and subsequent instability, driven primarily by fluctuations in the share price rather than changes in operational profitability.

Operating Profitability Trend

Operating profit per share exhibited a consistent decline during the initial period, falling from 82.78 USD in March 2022 to 34.96 USD by March 2024. From April 2024 through March 2026, this metric entered a stabilization phase, maintaining a narrow range between 33.84 USD and 36.50 USD.

Price to Operating Profit (P/OP) Expansion

The P/OP ratio rose substantially from a low of 7.98 in March 2022 to a peak of 30.86 in June 2024. This expansion was characterized by a divergent trend where the share price climbed toward 1,093.14 USD while operating profits per share simultaneously diminished, indicating a significant increase in the valuation multiple applied to operating earnings.

Valuation Correction and Subsequent Volatility

Following the June 2024 peak, the P/OP ratio underwent a rapid contraction, descending to 15.42 by June 2025. This correction coincided with a sharp reduction in share price. The final period observed moderate volatility, with the ratio ascending to 22.90 in December 2025 before moderating to 19.83 by March 2026, reflecting a market price that remained sensitive despite the relative steadiness of operating profits.

The valuation of the company, as measured by the Price to Sales (P/S) ratio, exhibited a period of significant expansion followed by a sharp contraction and subsequent volatility between March 2022 and March 2026. The ratio is primarily driven by fluctuations in the share price, as sales per share remained relatively stable or showed gradual growth over the same period.

P/S Ratio Expansion Phase

From March 31, 2022, to June 30, 2024, the P/S ratio experienced a steady upward trajectory, rising from 4.40 to a peak of 8.93. This expansion was largely catalyzed by a substantial increase in the share price, which climbed from 660.86 to 1,093.14. During this interval, sales per share did not grow proportionally, reaching a low of 111.35 in December 2022 before recovering to 122.37 by June 2024, indicating that the valuation increase was driven by market sentiment or price appreciation rather than fundamental revenue growth.

P/S Ratio Contraction Phase

A significant correction occurred between June 30, 2024, and June 30, 2025, during which the P/S ratio fell from its peak of 8.93 to 4.17. This decline coincided with a sharp reduction in the share price, which dropped from 1,093.14 to 558.87. Notably, this contraction in the valuation ratio occurred even as sales per share continued to improve, increasing from 122.37 to 134.11, suggesting a decoupling of the stock price from the underlying revenue performance.

Recent Valuation Trends

In the final period from June 30, 2025, to March 31, 2026, the P/S ratio demonstrated instability, recovering to 5.71 in December 2025 before retreating to 4.82 by March 2026. During this timeframe, sales per share maintained a consistent growth trend, reaching 142.31. The resulting volatility in the P/S ratio indicates that share price movements continued to be the primary driver of the valuation metric, offsetting the positive trend in revenue per share.

Revenue Performance Correlation

Sales per share showed a general recovery and growth pattern starting from a trough of 111.35 in December 2022 to 142.31 by March 2026. The fact that the P/S ratio ended the period at 4.82—close to its March 2022 level of 4.40—despite the increase in sales per share suggests a normalization of the valuation multiple following the peak in mid-2024.

The equity valuation trajectory is characterized by a divergence between the consistent growth of the book value per share and the volatility of the market share price. While the intrinsic book value increased monotonically throughout the observation period, the Price to Book Value (P/BV) ratio experienced a period of expansion followed by a significant contraction.

Book Value per Share (BVPS) Trend

A steady and uninterrupted increase in BVPS is observed, rising from 181.30 US$ in March 2022 to 299.73 US$ by March 2026. This consistent growth indicates a sustained accumulation of net assets relative to the number of shares outstanding over the entire period.

P/BV Ratio Expansion and Peak

The P/BV ratio maintained a range between 3.21 and 3.96 from March 2022 through December 2023. A valuation peak was reached on June 30, 2024, where the ratio hit 4.27, driven by a peak share price of 1,093.14 US$.

Valuation Compression

A sharp downward trend in the P/BV ratio occurred between June 30, 2024, and June 30, 2025, with the ratio falling from 4.27 to a period low of 1.98. This compression was primarily a result of the share price declining to 558.87 US$ while the BVPS continued to rise, effectively lowering the market premium over the book value.

Recent Valuation Stabilization

Between June 2025 and March 2026, the P/BV ratio exhibited moderate volatility, recovering to a high of 2.62 in December 2025 before settling at 2.29 by March 31, 2026. The current valuation reflects a lower market multiple compared to the 2022-2024 period, despite the significantly strengthened book value base.